How to Reduce Your Cosmetic Unit Cost Without Changing the Formula
How to Reduce Your Cosmetic Unit Cost Without Changing the Formula
The formula is rarely where the savings are. Four levers — packaging, raw-material sourcing, run volume, and over-formulation — to cut your cosmetic unit cost without your customers noticing a thing.
The formula is rarely where the savings are. On most personal-care SKUs, the fastest unit-cost reductions come from four levers that leave the formula untouched: packaging, raw-material sourcing, run volume (MOQ tier), and a concentration audit for over-formulation. Work them in that order, and a 10–20% reduction is realistic on many products without your customers noticing a thing.
A founder once asked me to cut 15% from her unit cost with one rule: "Don't change the formula. Our customers will notice." I hear that often — and honestly, the formula is the last place I look. The reason is simple: by the time you have a finished product, the formula is usually a small and fixed slice of the unit cost, while the things wrapped around the formula — the bottle, the carton, the way materials are bought, the size of your production run — are large and very much still negotiable. Here's where the money actually hides, in the order I work it.
A quick orientation before the levers. When a contract manufacturer quotes you a single "unit cost," they're bundling at least six things into one number: the bulk formula, primary packaging (the bottle, jar, pump, or tube that touches the product), secondary packaging (carton, label, insert), fill and labor, quality control, and overhead/margin. On a typical illustrative skincare SKU, the bulk formula might be 20–35% of that number and packaging another 30–50% — which is exactly why "change the formula" is the wrong instinct. You're trying to shrink the smallest box on the shelf while three bigger ones sit untouched.
Lever 1: Packaging (usually the fastest win)
Primary and secondary packaging is almost always the quickest lever, because it's where founders accept the manufacturer's default without questioning it. Three moves:
- Stock instead of custom. A custom bottle or cap can cost multiples of a functionally identical stock component, and it carries its own tooling and minimums. Moving to stock — without changing the form factor your customer holds — can take real cost out of a unit.
- Re-quote the component. The same stock part is often available from more than one supplier at meaningfully different prices. Brands rarely re-bid packaging after launch.
- Right-size the spec. Heavier glass, unnecessary secondary cartons, or over-engineered closures add cost that the customer experience doesn't require.
Take an illustrative 50 ml serum that launched in a custom-molded glass bottle with a custom dropper, boxed in a rigid carton. The founder chose all three at launch because the brand deck called for a "premium unboxing," and the CM simply quoted what was specified. On review, three things stood out. The custom bottle required its own tooling and a high minimum, and a near-identical stock dropper bottle in the same glass weight was available off the shelf. The dropper assembly was being single-sourced; a second qualified supplier quoted the same part for noticeably less. And the rigid carton — beautiful, but functionally redundant for a product sold mostly online and shipped in a mailer — was adding cost to every single unit for a moment most customers experience once. Swapping to the stock bottle, re-bidding the dropper, and moving from a rigid carton to a lighter folding carton (illustrative numbers) took a double-digit percentage out of the packaging line without changing one thing about how the product looked on a shelf or performed in the hand.
The pattern underneath all three moves is the same: packaging decisions get made once, under launch pressure, and then never revisited — even as your volume grows and better options open up. On many SKUs, packaging changes alone can move unit cost by a noticeable margin — often the difference between a product that's marginally profitable and one that funds your next launch. (For how packaging flows into your full cost, see The Product Brief and Bill of Materials guide.)
Lever 2: Raw-material sourcing
First-run formulas are built around your contract manufacturer's default supplier relationships, and the manufacturer typically marks up materials before passing the cost to you. You often have no visibility into whether an ingredient costs a few dollars a kilo or several times that — you just see the blended number at the bottom.
At meaningful volume, two moves change the math:
- Qualify a secondary supplier for commodity ingredients, so you're not single-sourced and can benchmark price.
- Specify (or go direct on) approved suppliers where your agreement allows, removing some of the material markup.
Imagine a moisturizer whose hero claim rests on a branded peptide complex, but whose cost is actually dominated by unglamorous, high-inclusion ingredients — the emollients, humectants, and a specialty emulsifier that together make up most of the formula by weight. The branded peptide is the thing the founder watches; the commodity base is where the dollars sit. If your CM is buying that base through a single distributor and marking it up before it reaches your invoice, you can be paying well above the market rate for materials that are chemically identical no matter who supplies them. Qualifying a second source for the commodity ingredients does two things at once: it gives you a real benchmark for what the materials should cost, and it removes the leverage a single-source supplier has over your price. Founders are often surprised to learn the savings come not from the expensive-sounding active but from the boring bulk of the formula.
This is where owning your formulation IP pays off directly: when you control the technical package — the full formula, the bill of materials, and the supplier specifications — you can see and influence each line instead of receiving one bundled "unit cost." A brand that doesn't own its formula is, by definition, negotiating in the dark. (More on that in our formulation IP ownership guide.)
Lever 3: Run volume and MOQ tier
Setup costs — changeover, cleaning, QC before the line starts — get amortized across every unit in a batch. Produce more units per run and the same fixed cost spreads thinner, so your effective cost per unit drops. Raw-material suppliers also offer better tier pricing at higher volumes, and your CM starts treating you as a consistent account rather than a one-off.
It helps to see why the first quote is always the ugly one. When a CM sets up to run your batch, a fixed block of cost happens regardless of whether they make 1,000 units or 10,000: the line has to be cleaned and changed over from the previous product, the batch has to be compounded and QC-tested, and someone has to set up, run, and tear down the fill. Spread that fixed block over 1,000 units and each one carries a heavy share of it; spread the same block over a larger run and the per-unit setup burden falls sharply. Layer on raw-material price breaks at higher purchase quantities and a CM who now sees you as a recurring account worth keeping, and the same formula in the same facility simply costs less to make per unit at volume.
The practical implication: the quote you got at your launch MOQ is the worst-case unit economics, not your steady state. I've watched founders kill a genuinely good product because the launch-run math looked thin, when the two-year-volume math would have been healthy. Before you conclude a product "doesn't work," model it at your realistic 12–24 month volume target, not your first cautious run. We break the volume mechanics down in detail in How MOQ and Production Volume Change Your Unit Cost (companion guide — link added when published).
Lever 4: The concentration audit (not a reformulation)
This is different from changing the formula. It's asking whether every active is at the right concentration. Over-formulation — using more of a premium active than the performance actually requires — is more common than founders think, especially in first formulas built quickly to hit a launch date. A formulator reviewing the formula against its claims can sometimes identify where a concentration is higher than it needs to be, trimming cost while holding performance.
Why does over-formulation happen in the first place? Usually because the first formula was built to work, fast, with generous margins of safety — not to be cost-optimized. A formulator under time pressure will often dose a hero active comfortably above the level needed for the claim, because the priority at that moment is a sample the founder approves, not a penny-optimized bill of materials. Once the product is selling, that headroom is real money. A disciplined review asks, for each costly active: what concentration does the claim and the supporting data actually require, and is the in-use level above that? Where it is, the level can sometimes be brought back toward the effective dose — and because the finished product performs the same, your customer doesn't experience a change. That's exactly the brief that founder gave me: don't let them notice.
Note: a concentration audit must be done by a qualified formulator and re-validated for stability and efficacy. It is not a DIY cost cut, and it is the one lever here that touches the formulation file — which is why I save it for last, after the no-risk packaging and sourcing wins are banked.
How to run the process
- Get an unbundled bill of materials from your CM — bulk, primary packaging, secondary packaging, fill/labor, QC, and overhead as separate lines. A single blended "unit cost" is a black box you can't negotiate. If your CM won't break it out, that reluctance is itself information.
- Attack packaging first (fastest and zero formula risk), then sourcing, then volume, then a concentration audit last (the only lever that touches the formula file).
- Re-model margin at your realistic 12–24 month volume, not your first run.
That 15% the founder wanted? We found it in packaging and a supplier change — levers one and two — and never touched levers three or four. Her formula never moved, and her customers never noticed anything except that the brand was still around the next year.
Frequently asked questions
Why is my cosmetic unit cost so high?
Most often it's packaging, low run volume (you're paying first-run setup costs spread over too few units), and bundled raw-material markups — not the formula itself. On a typical SKU the formula is a minority of the unit cost; the things around it are the majority.
Can I lower unit cost without reformulating?
Yes. Packaging changes, re-sourcing raw materials, increasing run volume, and a formulator-led concentration audit all reduce cost while keeping the customer-facing product the same. Only the last of those touches the formulation file at all.
How much does MOQ affect cosmetic unit cost?
Significantly. Setup costs amortize across the batch and suppliers offer volume tiers, so the same formula and CM can cost meaningfully less per unit at higher volumes. Model your steady-state volume, not your launch run.
Should I switch manufacturers to save money?
Not before you understand what's driving your current cost. A cheaper quote that omits stability testing, certifications, or IP protections often costs more than it saves — and re-bidding your existing packaging and materials usually recovers most of the gap without the disruption of moving.
Where do I even start if I only do one thing?
Get the unbundled BOM and re-quote your packaging. It's the fastest, lowest-risk dollar in the building, and it tells you whether the rest of the exercise is worth running.
Want the breakdown across volumes?
A unit-cost breakdown across production volumes for your formula is a spreadsheet conversation, not a guessing game. Bring your numbers — we'll show you where the savings actually are.
Book a Discovery CallNo obligation · 20–30 minutes · Loren@healthandbeautypartners.com